Chemoprevention strategies reduce malaria disease and death, but the efficacy of anti-
malarial drugs used for chemoprevention is perennially threatened by drug resistance. This …

Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …

Malaria cases and deaths remain unacceptably high and are resurgent in several settings,
though recent developments inspire optimism. This includes the approval of the world's first …

Background Subcutaneous administration of the monoclonal antibody L9LS protected adults
against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal …

Seasonal malaria chemoprevention (SMC) consists of the intermittent administration of a 3
day course of anti-malarial medications during the months of highest malaria risk in the …

Background Seasonal malaria chemoprevention (SMC) has shown high protective efficacy
against clinical malaria and severe malaria in a series of clinical trials. We evaluated the …

Invasion of the malaria vector Anopheles stephensi across the Horn of Africa threatens
control efforts across the continent, particularly in urban settings where the vector is able to …

Background Although the malaria burden has substantially decreased in sub-Saharan
Africa, progress has stalled. We assessed whether mass administration of ivermectin (a …

Background Seasonal malaria chemoprevention is used in 13 countries in the Sahel region
of Africa to prevent malaria in children younger than 5 years. Resistance of Plasmodium …

Background Sulfadoxine-pyrimethamine (SP) is recommended in Africa in several
antimalarial preventive regimens including Intermittent Preventive Treatment in pregnant …